Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
Advertisement
GPC-100 is a a small molecule CXCR4 inhibitor that showed promising preclinical activity in combination with cytarabine.
The award provides early-career researchers at NCCN Member Institutions with $150,000 in funding to support cancer research.
Nicholas Freedman, DO, presented on symptom management and supportive care at the Tri-State Blood Cancer Conference.
More than 240 meetings were held with members of Congress as part of the ASCO 10th Annual Advocacy Summit.
Joseph G. Jurcic, MD on the journey to survivorship for adults with either AML or ALL.
This agent which has newly received an ODD for MDS recalibrates the immune system to attack hematological and solid tumors.
Overall survival was also greater in the study comparing the treatments in ALL, AML, MDS, and mixed-phenotype acute leukemia.
Readmission rates were higher among patients with AML with high incomes compared with patients with low incomes.
A systemic review found that 21 of 90 randomized controlled trials for AML reported on patients' race and ethnicity.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
The trial will evaluate the safety, optimal dosing, and CR rate and duration of Actimab-A, venetoclax, and ASTX-727 in AML.
Clinical development of AUTX-703 is planned to begin in the first quarter of 2025.
The phase 2 prospective trial with these results also evaluated overall survival, nonrelapse mortality, and relapse rates.
The amended protocol includes reducing the size of the MIRACLE trial by approximately 10%.
A new study protocol plans for two phase III trials to evaluate the agent in intensive and nonintensive combinations for AML.
The first study on the efficacy and safety of an IDH1 inhibitor and hypomethylating agent in advanced AML shows success.
This new indication for the injection alkylating agent pertains to adult or pediatric patients aged one year and older.
The US cancer mortality rate has declined by 34%, but the incidence of leukemia and other malignancies is increasing.
In a phase 1 trial presented at ASH 2024, clinical benefit was observed in 100% of patients receiving LYT-200 monotherapy.
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
Quizartinib is a novel, second-generation, selective type II FLT3 inhibitor approved in the US for FLT3-ITD–positive AML.
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Advertisement
Section Editor
Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Advertisement
Latest News
April 17, 2025
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.